Study: Phase III randomized trial of concurrent chemoradiation with or without atezolizumab in limited-stage SCLC.

Key data: No improvement in OS (HR 0.99) or PFS (HR 0.88) with the addition of atezolizumab; survival outcomes overlapping between arms; toxicity modestly increased with IO.

Why it matters: Defines a clear negative result and contrasts sharply with the success of consolidation durvalumab in stage III NSCLC.

Clinical context & caveats: Details of PCI use, CNS progression patterns, and subsequent therapy still matter for interpretation, but the primary message is clear: CRT remains the backbone here, and IO should not be assumed additive in this setting.

Link

Study: Double-blind phase III (Japan/Korea/Taiwan) in treatment-naïve advanced non-squamous NSCLC: nivolumab vs placebo added to CP + bevacizumab.

Key data: 4-year OS around 35% (HR 0.71); durable survival plateau in responders; no late-emerging safety signals.

Why it matters: Supports long-term durability of IO-chemotherapy-anti-angiogenic strategies in selected patients.

Clinical context & caveats: Tumor assessments by independent review were not continued through the full 4-year window (investigator-assessed endpoints dominate later follow-up), and subsequent immunotherapy was common in the placebo arm; if anything, making the sustained OS separation more notable.

Link

Study: Exploratory phase III analysis stratifying perioperative nivolumab benefit by nodal involvement in resectable stage III NSCLC.

Key data: Benefit was strongest in pathologic N2: EFS HR 0.60. In contrast, the signal was smaller in N0–1 subgroups.

Why it matters: Helps operationalize perioperative chemo-IO: anatomic risk (especially N2) continues to track with magnitude of benefit, supporting risk-adapted intensity and follow-up.

Clinical context & caveats: Subgroup/exploratory, not practice-changing alone, but directionally consistent with the biology (higher relapse risk → more room for benefit).

Link

Study: Joint analysis of two randomized trials evaluating upfront strategies combining osimertinib with SRS approaches in EGFR-mutant NSCLC brain metastases.

Key data: Improved intracranial control without OS detriment; reduced need for salvage WBRT. 12-month intracranial PFS 57% vs 68%; median intracranial PFS 21.9 vs 17.2 months; median OS 29.1 vs 46.1 months.

Why it matters: High-value, real-world-relevant data on CNS sequencing; exactly the space where practice variation is large and outcomes hinge on strategy.

Clinical context & caveats: Cross-trial harmonization and treatment heterogeneity can complicate interpretation, but the results strongly support that how we deploy local therapy alongside osimertinib materially affects CNS control and downstream outcomes.

Link

Study: Nonrandomized population-based phase II trial of SABR for patients with up to 5 oligometastatic lesions; long-term follow-up.

Key data: Median OS 42.1 months; 5-year OS 39.2%; 5-year PFS 19.2%; local control 5-year 72.7%.

Why it matters: Reinforces that oligometastatic SABR can deliver meaningful long-term survival tails in appropriately selected patients. Useful when counseling and selecting for aggressive local therapy.

Clinical context & caveats: Nonrandomized; selection drives outcomes. Still, the durability supports SABR as more than palliation in selected biology.

Link

Study: Pooled analysis of early-phase trials in EGFR-mutated NSCLC of a first-in-class EGFR–HER3 bispecific ADC.

Key data: In EGFR-mutated NSCLC, ORR 57.5% vs 43.0% across the pooled cohorts reported; median PFS 9.0 vs 7.0 months.

Why it matters: Adds momentum to the post-TKI landscape where ADCs are emerging as high-activity options and where HER3 biology continues to look targetable.

Clinical context & caveats: Early-phase pooling; cross-cohort heterogeneity and evolving dosing mean durability/safety characterization is still in progress.

Link

Study: Single-arm phase II neoadjuvant camrelizumab + apatinib in resectable NSCLC with long-term outcomes and ctDNA dynamics.

Key data: 3-year OS 82.5%; ctDNA clearance/kinetics associated with outcomes.

Why it matters: Supports the concept that ctDNA dynamics can complement imaging/pathology to risk-stratify after neoadjuvant IO-based approaches.

Clinical context & caveats: Single-arm; regimen is not a global standard; biomarker work is hypothesis-generating until prospectively embedded in randomized perioperative programs.

Link

Study: Phase II trial testing FMT combined with immunotherapy in NSCLC and melanoma cohorts.

Key data: The paper reports improved clinical activity in subsets alongside microbiome remodeling; however, effect sizes are cohort- and design-dependent.

Why it matters: A credible step toward translating microbiome modulation into interventional oncology, beyond associative studies.

Clinical context & caveats: Early-phase; implementation/logistics and generalizability remain key barriers; not ready for routine practice.

Link

Study: Phase III superiority randomized trial testing an ultra-low-dose IO strategy in refractory solid tumors (platform relevance).

Key data: Ultra-low-dose immunotherapy improved overall survival versus standard dosing (HR 0.86, 95% CI 0.78–0.95), with a marked reduction in grade ≥3 immune-related adverse events (~8% vs ~22%). Survival benefit was preserved despite dose de-escalation, indicating a more favorable therapeutic index.

Why it matters: Even if not lung-specific, it’s a provocative dose-strategy concept clinicians will hear about; useful to have it on the radar without over-weighting it in a thoracic brief.

Clinical context & caveats: Tumor-agnostic mix; translation to lung cancer practice is indirect.

Link

LU005 in LS-SCLC is important negative data — don’t assume IO always adds on top of CRT.

TASUKI-52 reinforces a real 4-year survival tail for IO + chemo + bevacizumab strategies.

Nodal burden continues to help identify where perioperative chemo-IO delivers the biggest incremental benefit.

CNS / RT integration: CNS sequencing with osimertinib + SRS remains a high-impact decision point; STARLET adds usable data to guide strategy.

Oligometastatic disease: SABR durability supports aggressive local therapy in carefully selected biology.

Several datasets are region-specific (e.g., East Asia trials), and subsequent therapy patterns can dilute or magnify observed OS differences.